Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q4 2023 Earnings Presentation
21 slides from Q-linea Ab's earnings presentation, Feb 27, 2024
Slide 1: Future Proof Healthcare
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q4(23) Jonas Jarvius, CEO & President Christer Samuelsson, CFO/IR Stuart Gander, CEO & President from 1st March
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea 4th quarter
Q-linea 4th quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Overview Geographical presence Key achievements in 2023 • Built a strong distribution partnership network in key geographies in EU Introduction to the company Acti
Slide 4: Stuart Gander comes in as new CEO & President
Stuart Gander comes in as new CEO & President Stuart Gander CEO & President from March 1st 2024 +17 years’ experience in global medtech industry and across diagnostics sector. History of strategic and operational creativity and supporting teams during high-growth and market change Selected experienc
Slide 5: Why is improved infectious disease diagnostics important?
Why is improved infectious disease diagnostics important? Sepsis Antimicrobial Resistance Rapid diagnostics could reduce mortality with up to 40%4) Has been presented as ~50% of all patients receive inappropriate treatment “The biggest threat to mankind” ~20% dies before current diagnostic provide r
Slide 6: ASTar workflow vs current workflow
Up to 48 hours faster actionable results DAY DAY DAY DAY 1 2 3 4 CURRENT WORKFLOW Plates are streaked Susceptibility Gram to perform a clean Patient blood draw stain culture Colony selection Determination (AST) Time to Optimized Blood bottle therapy Actionable Rapid ID Overnight 0.5 McFarland incuba
Slide 7: Large addressable market for rAST from blood cultures
Large addressable market for rAST from blood cultures And large follow-up market for other samples Sepsis Additional opportunities Lower respiratory tract infection Positive blood cultures 1) Assume 20% eligible for If equally divided by selected current Respiratory 20M testing with rAST 1) rAST pro
Slide 8: ASTar brings a broad panel, full automation and ease of use
ASTar bring a broad panel, full automation and ease of use in one system Time to actionable results is key in sepsis diagnostics Fully-automatic: ASTar combines: • Fully-automatic. Less than 2 min hands-on time • Random access • High throughput – 12 samples in parallel • Fastidious & non-fastidious
Slide 9: Commercialisation footprint – strong footprint in EU and the USA
Commercialisation footprint – 2023 was important to create a strong footprint in EU and the USA We started 2023 with commercial activity in Sweden – and with a competitive We closed 2023 with a strong distribution network in all key geographies in EU product and with two subsidiaries in Italy and US
Slide 10: ASTar performs well in customer evaluations
ASTar performs well in customer evaluations rAST is a new field in Europe and all customers want to try before they commit “ASTar fits right into our processes and systems” Robert Price, Senior Biomedical Scientist, Whiston Hospital, UK Large multicentre evaluation in Germany and UK Covered 500 ASTa
Slide 11: ASTar enables anyone at the lab to load samples anytime
ASTar enables anyone at the lab to load samples anytime Click “start” Scan barcode Add sample Load AST disc Add sample barcode Less than 2 minutes hands on Click “Start run” time from blood culture bottle to start a run Minimal training required Source: Company information and webpage 11
Slide 12: ASTar EU-IVDR Gram negative panel – the broadest AST panel in EU
ASTar EU-IVDR Gram negative panel – the broadest AST panel in EU* ASTar AST disc: 336 reaction wells in a 120 mm CD format. 10 different sectors i.e. fastidious and non-fastidious conditions. ASTar Instrument and ASTar BC G- Kit are CE IVDR-marked but not FDA 510(k)-cleared and not available for sal
Slide 13: ASTar wins the first public tender for rAST in Italy
ASTar wins the first public tender for rAST in Italy Tor Vergata tender outcome, Quote value € Financial score Technical score Total score Rank bioMérieux 439,619 30 52.13 82.13 2 Quantamatrix 588,750 22.4 49.6 72 3 Accelerate Diagnostics 0 n.a. Q-linea 598,000 22.05 64.83 86.88 1 The rAST market is
Slide 14: USA – Q-linea Inc.
USA – Q-linea Inc. The US market is coming closer FDA discussions indicates that we are coming closer to clearance (approval) • Final details are discussed but no major questions or concerns Most important market due to size and demonstrated to be more mature for rAST than Europe • Two Early Access
Slide 15: Way forward for Podler
Way forward for Podler Several business opportunities are being evaluated After the period end the board decided to place the Podler asset in a separate company • Fully owned subsidiary • Purpose is to enable continuation of ongoing business discussions • Enable separate focus for both for Podler an
Slide 16: We are expecting an interesting conference at AMCLI
We are expecting an interesting conference at AMCLI Q-linea will host a workshop at Italian Association for Clinical Microbiology Two interesting session at the workshop 9th March 2024 • Prof. Alexia Verroken, from Cliniques Universitaires Saint-Luc, Brussels • Comparative analysis of Q-linea’s ASTa
Slide 17: Unique technology enables disruptive expansion pipeline & opportunities
Unique technology enables disruptive expansion pipeline & opportunities Product 1 to 3 years 3 to 5 years ASTar® CE IVD Extended panels Expansion Expansion Expansion BC G- & capabilities Isolates Urine other indications On market and in development Podler® The board has decided to place Podler in a
Slide 18: Consolidated statement of profit and loss
Consolidated statement of profit and loss Fourth quarter: • Lower sales than anticipated due to slower conversion of sales funnel/longer lead times • Operating result SEK -55,4 million (-59,6) or -18.5M on average per month • -19.5M on average for the first nine months • Improvement thanks to lower
Slide 19: Consolidated statement of financial position - end of fourth quarter
Consolidated statement of financial position - end of fourth quarter • Cash and cash equivalents amounted to SEK 81.9 million (72.9) • Remaining loan facility from main owner of SEK 41.5 million (0) • Total: SEK 123.4 million availale funds Dec 31, 2023. • Inventories amounted to SEK 46.5 million (4
Slide 20: Future financing
Future financing • Q-linea does not yet generate positive cash flow from its operations • Q-linea reported that we do not have “going concern” • As previously stated we have a total of SEK 123.4 millions in available funds at year end and an average operating result of SEK -18.5 million in the fourt
Slide 21: Thank you!
Thank you! Q-linea wants to contribute to a healthier society by future-proofing a new generation of healthcare professionals, labs and hospitals 21